You are here

Revlimid

FDA Action Alert: Regeneron, Sanofi, Celgene

BioSpace

Mon, 06/24/19 - 07:27 pm

Acer Therapeutics

Dova Pharmaceuticals

Nabriva Therapeutics

Meet the Top Ten Drugs of 2024 (Maybe)

Drug Channels

Tue, 06/18/19 - 11:46 pm

Bristol-Myers Squibb

Celgene gets FDA nod for blood cancer drug combo Revlimid plus rituximab

Pharmaceutical Business Review

Wed, 05/29/19 - 09:55 am

follicular lymphoma

marginal zone lymphoma

Morphosys to take on CAR-Ts in NHL with promising antibody

Pharmaforum

Mon, 05/20/19 - 11:02 pm

non-Hodgkin lymphoma

clinical trials

After years of delays, NICE backs Celgene’s Revlimid in first-line MM

Pharmaforum

Fri, 05/17/19 - 07:18 pm

Multiple Myeloma

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

Yahoo/Reuters

Thu, 03/14/19 - 10:18 am

Multiple Myeloma

Celgene gets fast FDA review of Revlimid combo in lymphoma

Pharmaforum

Wed, 02/27/19 - 10:49 am

priority review

Celgene's Revlimid defenses withstand another challenge

Biopharma Dive

Tue, 02/12/19 - 10:14 am

Multiple Myeloma

The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss

Fierce Pharma

Fri, 01/4/19 - 11:59 pm

Bristol-Myers Squibb

Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma

Fierce Pharma

Sat, 11/3/18 - 04:05 pm

follicular lymphoma

Celgene to launch five new products through to 2020

PM Live

Mon, 10/29/18 - 07:02 pm

Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete

Motley Fool

Fri, 09/7/18 - 11:28 am

Can Celgene's latest Revlimid win reverse the company's bad-news streak?

Fierce Pharma

Tue, 07/24/18 - 06:00 pm

clinical trials

non-Hodgkin lymphoma

With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?

Fierce Pharma

Thu, 07/12/18 - 06:30 pm

AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024

Fierce Pharma

Fri, 06/8/18 - 09:48 am

Bristol-Myers Squibb

5 Best-Selling Orphan Drugs in the U.S.

Motley Fool

Wed, 05/30/18 - 09:13 pm

Teva Pharmaceutical

Bristol-Myers Squibb

Here's Where Things Went Wrong for Celgene Corporation in 2017

Motley Fool

Fri, 12/29/17 - 10:44 am

autoimmune disease

Celgene shares sink after another PhIII lymphoma flop and J&J steps up for the late-stage BCMA race

Endpoints

Sat, 12/23/17 - 12:04 pm

clinical trials

follicular lymphoma

Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst

Fierce Pharma

Tue, 10/24/17 - 05:33 pm

3 Big Pharma Stocks Set to Succeed

Motley Fool

Thu, 10/5/17 - 09:36 am

Pages